Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Galle P.R.Finn R.S.Qin S.Ikeda M.Zhu A.X.Kim T.-Y.Kudo M.Breder V.Merle P.Kaseb A.Li D.Mulla S.Verret W.Xu D.-Z.Hernandez S.Ding B.Liu J.Huang C.Lim H.Y.ANN-LII CHENGDucreux M.2022-02-212022-02-2120211470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108809205&doi=10.1016%2fS1470-2045%2821%2900151-0&partnerID=40&md5=a1c633915becd241fc3e5b6b4fdd3d1ehttps://scholars.lib.ntu.edu.tw/handle/123456789/594879Background: Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150[SDGs]SDG3alpha fetoprotein; atezolizumab; bevacizumab; sorafenib; angiogenesis inhibitor; antineoplastic agent; atezolizumab; bevacizumab; monoclonal antibody; protein kinase inhibitor; sorafenib; abdominal swelling; adult; advanced cancer; Article; body image; caPatient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialjournal article10.1016/S1470-2045(21)00151-0340518802-s2.0-85108809205